Radioguided sentinel lymph node dissection in patients with localised prostate carcinoma: Influence of the dose of radiolabelled colloid to avoid failure of the procedure

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 1, 2008, Pages 32-38

  Brenot Rossi, Isabelle ^a   Rossi, Dominique ^b   Esterni, Benjamin ^a   Brunelle, Serge ^a   Chuto, Guillaume ^a   Bastide, Cyrille ^b  

^a INSTITUT PAOLI CALMETTES   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Prostate cancer; Prostate carcinoma; Sentinel lymph node; Sentinel node

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; RHENIUM TECHNETIUM TC 99M; TRACER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER PATIENT; CANCER SURGERY; COLLOID; CONTROLLED STUDY; GLEASON SCORE; HUMAN; ILIAC CREST; ISOTOPE LABELING; LYMPH NODE DISSECTION; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; PROSTATE CARCINOMA; RADIATION DOSE; RISK ASSESSMENT; SENTINEL LYMPH NODE; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE;

ADULT; AGED; COLLOIDS; DISSECTION; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RADIATION DOSAGE; RADIOACTIVITY; SENTINEL LYMPH NODE BIOPSY; SURGERY, COMPUTER-ASSISTED; TREATMENT OUTCOME;

EID: 36849090839     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0516-0     Document Type: Article

References (26)

1. El-Galley RE, Keane TE, Petros JA, Sanders WH, Clarke HS, Cotsonis GA, et al. Evaluation of staging lymphadenectomy in prostate cancer. Urology 1998;52:663-667.
2. Haese A, Epstein JI, Huland H, Partin AW. Validation of a biopsy-based pathologic algorithm for predicting lymph node metastases in patients with clinically localized prostate carcinoma. Cancer 2002;95:1016-1021.
3. Häcker A, Jeschke S, Leeb K, Prammer K, Ziegerhofer J, Sega W, et al. Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. J Urol 2006;176:2014-2019.
4. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, Hulsbergen van de Kaa C, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003;348:2491-2499.
5. Weckermann D, Dorn R, Trefz M, Wagner T, Wawroschek F, Harzmann R. Sentinel lymph node dissection for prostate cancer: experience with more than 1,000 patients. J Urol 2007;177:916-920.
6. American Joint Committee on Cancer. Cancer staging handbook: TNM classification of malignant tumors, 6th edn. Berlin Heidelberg New York: Springer; 2002.
7. Gandwindt U, Paulsen F, Corvin S, Hundt I, Alber M, Frey B, et al. Optimized coverage of high-risk adjuvant lymph node areas in prostate cancer using a sentinel node-based, intensity-modulated radiation therapy technique. Int J Rad Oncol Biol Phys 2007;67:347-355.
8. Beri A, Janetschek G. Technology insight: radioguided sentinel lymph node dissection in the staging of prostate cancer. Nature Clin Pract Urol 2006;3:602-610.
9. Corvin S, Schilling D, Eichhorn K, Hundt I, Hennenlotter J, Anastasiadis AG, et al. Laparoscopic sentinel lymph node dissection-a novel technique for the staging of prostate cancer. Eur Urol 2006;49:280-285.
10. Corvin S, Schilling D, Anastasiadis AG, Bares R, Stenzl A, Kuczyk M. Radioisotope guided pelvic lymph node dissection for prostate cancer staging. Eur Urol Suppl 2005;4:25-27.
11. Jeschke S, Nambirajan T, Leeb K, Ziegerhofer J, Sega W, Janetschek G. Detection of early lymph node metastases in prostate cancer by laparoscopic radioisotope guided sentinel lymph node dissection. J Urol 2005;173:1943-1946.
12. Weckermann D, Goppelt M, Dorn R, Wawroschek F, Harzmann R. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of ≤10 ng/ml and biopsy Gleason score of ≤6, and their influence on PSA progression-free survival after radical prostatectomy. BJU Int 2006;97:1173-1178.
13. Krengli M, Ballarè A, Cannillo A, Rudoni M, Kocjancic E, Gianfranco L, et al. Potential advantage of studying the lymphatic drainage by sentinel node technique and SPECT-CT image fusion for pelvic irradiation of prostate cancer. Int J Rad Oncol Biol Phys 2006;66:1100-1104.
14. Takashima H, Egawa M, Imao T, Fukuda M, Yokoyama K, Namiki M. Validity of sentinel lymph node concept for patients with prostate cancer. J Urol 2004;171:2268-2271.
15. Warncke SH, Mattei A, Fuechsel F, Z'Brun S, Krause T, Studer UE. Detection rate and operating time required for γ probe guided sentinel lymph node resection after injection of technetium-99m nanocolloid into the prostate with and without preoperative imaging. Eur Urol 2007;52:126-133.
16. Weckermann D, Dorn R, Holl G, Wagner T, Harzmann R. Limitations of radioguided surgery in high-risk prostate cancer. Eur Urol 2007;51:1549-1558.
17. Weckermann D, Wawroschek F, Harzmann R. Is there a need for pelvic lymph node dissection in low risk prostate cancer patients prior to definitive local therapy? Eur Urol 2005;47:45-51.
18. Wawroschek F, Wagner T, Hamm M, Weckermann D, Vogt H, Märkl B, et al. The influence of serial sections, immunohistochemistry, and extension of pelvic lymph node dissection on the lymph node status in clinically localized prostate cancer. Eur Urol 2003;43(2):132-137.
19. Wawroschek F, Vogt H, Weckermann D, Wagner T, Hamm M, Harzmann R. Radioisotope guided pelvic lymph node dissection for prostate cancer. J Urol 2001;166(5):1715-1719.
20. Wawroschek F, Vogt H, Wengenmair H, Weckermann D, Hamm M, Keil M, et al. Prostate lymphoscintigraphy and radio-guided surgery for sentinel lymph node identification in prostate cancer. Technique and results of the first 350 cases. Urol Int 2003;70(4):303-310.
21. Brenot-Rossi I, Bastide C, Garcia S, Dumas S, Esterni B, Pasquier J, et al. Limited pelvic lymphadenectomy using the sentinel lymph node procedure in patients with localised prostate carcinoma: a pilot study. Eur J Nucl Med Mol Imaging 2005;32:635-640.
22. Brenot-Rossi I, Houvenaeghel G, Jaquemier J, Bardou VJ, Martino M, Hassan-Sebbag N, et al. Nonvisualization of axillary sentinel node during lymphoscintigraphy: is there a pathologic significance in breast cancer? J Nucl Med 2003;44:1232-1237.
23. Schwartz GF, Giuliano AE, Veronesi U; Consensus Conference Committee. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Philadelphia, Pennsylvania. Cancer 2002;94:2542-2551.
24. Alazraki N, Glass EC, Castronovo F, Valdés Olmos RA, Podoloff D. Procedure guideline for lymphoscintigraphy and the use of intraoperative gamma probe for sentinel lymph node localization in melanoma of intermediate thickness 1.0. J Nucl Med 2002;43:1414-1418.
25. Eshima D, Fauconnier T, Eshima L, Thornback JR. Radiopharmaceuticals for lymphoscintigraphy: including dosimetry and radiation considerations. Semin Nucl Med 2000;30:25-32.
26. Wengenmair H, Kopp J, Wawroscheck F, Grober S, Dorn R, Heidenreich P. Pelvic lymph node diagnosis in prostatic carcinoma: biokinetics and dosimetry of 99mTc-nanocolloid after intraprostatic injection. Nuklearmedizin 2002;41:102-107.